Progenitor cell combination normalizes retinal vascular development in the oxygen-induced retinopathy (OIR) model

Calzi, Sergio Li; Shaw, Lynn C.; Moldovan, Leni; Shelley, W. Christopher; Qi, Xiaoping; Racette, Lyne; Quigley, Judith; Fortmann, Seth D.; Boulton, Michael E.; Yöder, Mervin C.; Grant, Maria B.

doi:10.1172/jci.insight.129224

Cited by 26 publications

(25 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In diabetes, these cells are defective, are low in number, and their levels inversely correlate with the presence of microvascular complications, such as DR (36,37). Cell replacement treatments using nondiabetic-derived vascular reparative cells have proven efficacious in DR mouse models (38), but drug treatments are needed that target and rejuvenate this population of circulating cells. In diabetic mice, LXR activation has been shown to restore the equivalent population of vascular reparative cells by enhancing their migration and suppressing oxidative stress and inflammatory gene expression (18).…”

Section: Introductionmentioning

confidence: 99%

Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes

Vieira¹,

Fortmann²,

Hossain³

et al. 2020

JCI Insight

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes

Vieira¹,

Fortmann²,

Hossain³

et al. 2020

JCI Insight

Self Cite

View full text Add to dashboard Cite

“…Notably, this vasoreparative effect was mimicked by administrating either conditioned media from ECFCs or human recombinant IGFBPs [80]. Furthermore, ECFCs stimulated retinal regeneration by supporting vascular development promoted by bone marrow-derived CD34 hematopoietic stem cells, as recently demonstrated in a murine model of OIR [81]. A follow-up study revealed that the injection of ECFCs-derived extracellular vesicles restored the vascular network in a murine model of OIR by stimulating local angiogenesis through the delivery of a package of multiple microRNAs (miRNAs) [82].…”

Section: 22mentioning

confidence: 71%

Therapeutic Potential of Endothelial Colony Forming Cells in Ischemic Disease: Strategies to Improve Their Regenerative Efficacy

Faris

Negri

Perna

et al. 2020

Preprint

View full text Add to dashboard Cite

Cardiovascular disease (CVD) comprises a group of heart and circulatory disorders, which are regarded as a global medical issue with high prevalence and mortality rates. Currently, vascular regenerative surgery represents the most employed therapeutic option to treat ischemic disorders, even though not all the patients are amenable to surgical revascularization. Therefore, more efficient therapeutic approaches are urgently required to promote neovascularization. Therapeutic angiogenesis represents an emerging strategy that aims at reconstructing the damaged vascular network by stimulating local angiogenesis and/or promoting de novo blood vessel formation according to a process known as vasculogenesis. Circulating endothelial colony forming cells (ECFCs), in turn, represent truly endothelial precursors able to aggregate into bidimensional tube networks and to originate patent vessels. Accordingly, ECFCs provide the most rationale and promising cellular candidate for therapeutic purposes. The current review provides a brief outline on the origin and characterization of ECFCs and a summary of the progress in preclinical studies aiming at assessing their efficacy in a variety of ischemic disorders, including AMI, PAD, ischemic brain disease and retinopathy. We also describe how to enhance the vasoreparative potential of ECFCs by boosting specific pro-angiogenic signalling pathways either pharmacologically or through gene manipulation. Taken together, these observations suggest that ECFCs represent a useful strategy to treat ischemic diseases.

show abstract

“… 84 Several groups have also reported the therapeutic potential of EPCs, although the protocols and the levels of commitment vary. 85 86 87 88 89 Medina et al reported that outgrowth endothelial cells, also called endothelial colony-forming cells, 90 with higher expression of CD105 or CD146 from peripheral blood mononuclear cells contributed to vascular repair and reduced the stimuli for pathological angiogenesis. 85 Prasain et al 86 demonstrated that outgrowth endothelial cells from human induced pluripotent stem cells reduced the avascular area and preretinal neovascular tufts.…”

Section: Potential Options Of Therapeutic Angiogenesis Against Ischemmentioning

confidence: 99%

“…In another study, cord blood-derived EPCs were effective in restoring pathological changes in mice with OIR. 87 A combination of bone marrow-derived CD34+ cells and vascular wall-derived endothelial colony-forming cells 88 or co-administration of a peptide based on the helix-B domain of erythropoietin 91 was suggested to enhance the therapeutic effects of EPCs in OIR mice.…”

Section: Potential Options Of Therapeutic Angiogenesis Against Ischemmentioning

confidence: 99%

Toward the Clinical Application of Therapeutic Angiogenesis Against Pediatric Ischemic Retinopathy

Kim

2020

J Lipid Atheroscler

View full text Add to dashboard Cite

Therapeutic angiogenesis refers to strategies of inducing angiogenesis to treat diseases involving ischemic conditions. Historically, most attempts and achievements have been related to coronary and peripheral artery diseases. In this review, we propose the clinical application of therapeutic angiogenesis for the treatment of pediatric ischemic retinopathy, including retinopathy of prematurity, familial exudative retinopathy, and NDP -related retinopathy. These diseases are all characterized by the reduction of physiological angiogenesis and the following induction of pathological angiogenesis. Therapeutic angiogenesis, which supplements insufficient physiological angiogenesis, may be a therapeutic approach for ischemic conditions. Various molecules and modalities can be utilized to apply therapeutic angiogenesis for the treatment of ischemic retinopathy, as in coronary and peripheral artery diseases. Experiences with cardiovascular diseases provide a useful reference for the further clinical application of therapeutic angiogenesis in pediatric ischemic retinopathy. Recombinant proteins and gene therapy are powerful tools to deliver angiogenic factors to retinal tissues directly. Furthermore, endothelial progenitor or bone marrow-derived cells can be injected into the vitreous cavity of the eye for therapeutic angiogenesis. Intraocular injections are highly promising for the delivery of therapeutics for therapeutic angiogenesis. We expect that therapeutic angiogenesis will be a breakthrough in the treatment of pediatric ischemic retinopathy.

show abstract

Progenitor cell combination normalizes retinal vascular development in the oxygen-induced retinopathy (OIR) model

Cited by 26 publications

References 41 publications

Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes

Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes

Therapeutic Potential of Endothelial Colony Forming Cells in Ischemic Disease: Strategies to Improve Their Regenerative Efficacy

Toward the Clinical Application of Therapeutic Angiogenesis Against Pediatric Ischemic Retinopathy

Contact Info

Product

Resources

About